secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2021-12-20T23:59:59+00:00
Accession:  0001564590-21-060676
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD appoints Hugh O'Dowd as CEO; founder Finizio becomes Vice Chair
------------------------------------------------------------------------------

- Hugh O'Dowd, formerly President, appointed CEO on Dec 14, 2021 and director on Dec 18.
- Robert G. Finizio steps down as CEO but remains Vice Chair of the Board.
- Finizio's separation is termination without 'Cause'; he receives contractual separation benefits.
- O'Dowd's existing employment agreement (filed Aug 9, 2021) continues unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/0001564590-21-060676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/txmd-8k_20211214.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-060676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer